CIKRIKCIOGLU, Mehmet AliSOYTAS, Rabia BagKILIC, ElifToprak, Aybala ErekKaratoprak, CUMALİCakirca, MUSTAFAZorlu, MEHMETKiskac, MUHARREMEMEGIL, SebnemCetin, GÜVENDogan, ELİF ECESEKIN, YahyaHAMDARD, Jamshid2019-10-052019-10-052016-06-01CIKRIKCIOGLU M. A. , SOYTAS R. B. , KILIC E., Toprak A. E. , Cakirca M., Zorlu M., Kiskac M., EMEGIL S., Cetin G., Dogan E. E. , et al., -CD40 ligand and P-selectin in heterozygous Beta-thalassemia-, JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, cilt.66, ss.699-704, 2016https://hdl.handle.net/20.500.12645/3463Objective: To investigate platelet functions and measure soluble CD40 ligand, soluble P-selectin, beta-thromboglobulin and platelet factor 4 levels in the blood of heterozygous beta thalassemia patients. Methods: The cross-sectional case-control study was conducted at Bezmialem Vakif University, Istanbul, Turkey, between September 2013 and April 2014, and comprised heterozygous beta thalassemia patients who were compared with 41 gender-, age- and body mass index-matched controls for platelet function markers. The two groups were also compared for co-morbidities, smoking, and regular medications. Results: Of the 78(78.78) subjects, 50(64%) were women and 28(36%) men with an overall mean age of 39.4±12.7 years (range: 18-79 years). The mean body mass index was 26.3±4.2. The heterozygous beta thalassemia group included 37(47%) subjects [24(65%) females; 13(35%) males] while the control group had 41(53%) [26(63%) females; 15(37%) males]. Soluble CD40 ligand and soluble P-selectin were lower in the heterozygous beta thalassemia group (p=0.009; p=0.010). Beta-thromboglobulin and platelet factor 4 levels were comparable between the groups (p=0.497; p=0.507.). Conclusions: Some platelet functions may be reduced in heterozygous beta thalassemia patients, which may be related to their lower incidence of cerebral and cardiac ischaemic events.eninfo:eu-repo/semantics/openAccessArticleWOS:0003766870000158496991705427339572